Business Context and Reporting Period
Milestone Pharmaceuticals Inc. (MIST) is a clinical-stage biopharmaceutical company focused on developing CARDAMYST (etripamil), a rapid-onset nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). This 10-K covers the fiscal year ended December 31, 2024. The company is awaiting a final FDA decision on its New Drug Application (NDA) for PSVT, with a Prescription Drug User Fee Act (PDUFA) goal date of March 27, 2025.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $1,000 |
| Net Loss | $(41,519) | $(59,685) |
| Operating Expenses | $42,102 | $62,098 |
| Cash and Cash Equivalents (Dec 31) | $25,314 | $13,760 |
| Short-term Investments (Dec 31) | $44,381 | $52,243 |
| Total Liquidity | $69,695 | $66,003 |
| Senior Secured Convertible Notes | $53,352 | $49,772 |
Notes: The company generated no revenue in 2024. The 2023 revenue of $1.0 million was a milestone payment from a licensing partner. Operating expenses decreased by 32.2% year-over-year, driven primarily by a 53.8% reduction in Research and Development (R&D) expenses following the completion of Phase 3 studies.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses declined from $62.1 million in 2023 to $42.1 million in 2024. R&D expenses dropped significantly due to the completion of pivotal Phase 3 trials for PSVT. Commercial expenses also decreased by 27.2% as the company implemented cost-saving measures.
- Capital Raise: In February 2024, the company completed an underwritten public offering of common shares and pre-funded warrants, raising net proceeds of approximately $31.9 million.
- Debt Position: The carrying value of the 2029 Convertible Notes increased to $53.4 million due to the accrual of payment-in-kind (PIK) interest.
- Cash Flow: Net cash used in operating activities improved to $28.8 million in 2024 from $46.4 million in 2023, reflecting the reduction in operational burn rate.
Guidance, Outlook, and Risks
Outlook and Catalysts: The primary near-term catalyst is the FDA's decision on the PSVT NDA by March 27, 2025. If approved, the company plans to launch CARDAMYST in the U.S. with a direct sales force. The company is also advancing a Phase 3 study for AFib-RVR, with patient enrollment anticipated in 2025.
Liquidity: Management expects existing cash, cash equivalents, and short-term investments ($69.7 million as of Dec 31, 2024) to fund operations for at least the next 12 months. However, the company anticipates continuing to incur substantial operating losses and will require additional funding for future development and commercialization.
Key Risks:
- Regulatory Approval: Failure to obtain FDA approval for PSVT or AFib-RVR would prevent commercialization and revenue generation.
- Capital Needs: Inability to raise additional capital could force delays or termination of development programs.
- Single Product Dependence: The company's success is entirely dependent on etripamil; it has no other approved products or significant revenue streams.
- Manufacturing and Supply: Reliance on third-party contract manufacturers and a single-source supplier for the nasal spray device introduces supply chain risks.
Investor Verification Checklist
- Verify the status of the FDA PDUFA decision for CARDAMYST (PSVT) expected on March 27, 2025.
- Confirm the timeline and enrollment progress for the Phase 3 AFib-RVR study.
- Assess the sufficiency of the $69.7 million liquidity runway against projected commercialization costs if approval is granted.
- Review the terms of the $50 million 2029 Convertible Notes, specifically the conversion price and PIK interest implications.
- Monitor the company's ability to secure additional financing if the FDA decision is delayed or negative.